Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma

The rapid evolution of genomic technologies over the last years has led to the development of different methods for the detection, measurement and analysis of cell-free DNA fragments (cfDNA) which are shed into the bloodstream by apoptotic cells and circulate at a low concentration in plasma. In cancer patients, the proportion of tumor-derived cfDNA is defined as circulating tumor DNA. This analysis, commonly known as liquid biopsy, allows to access tumor DNA through a simple blood sampling and therefore without the need of an invasive tissue biopsy. For this reason, this tool may have several clinical applications in terms of diagnosis, prognosis, and monitoring of minimal residual disease. However, there are still several critical issues that need to be resolved. In this review, we will discuss some of the controversies around this method and its potential clinical applications.

Automated summary

The rapid evolution of genomic technologies has led to the development of different methods for the detection, measurement and analysis of cell-free DNA fragments (cfDNA) shed into the bloodstream. This analysis, known as liquid biopsy, allows for accessing tumor DNA through a simple blood sampling, potentially serving clinical applications in terms of diagnosis, prognosis, and monitoring of minimal residual disease.